A method for the treatment of: A. a disease state or condition mediated by a kinase wh ich is BCR-abl, VEGFR, PDGFR, EGFR, FLT3, JAK, C-abl, PDK1, Chk, FGFR, Ret, Eph, or Src； or B. a cancer in which the cancer cells thereof contain a drug resistant kinase mutation which is: (a) a threonine gatekeeper mutation； or (b) a drug-resistant gatekeeper mutation； or (c) an imatinib resistant mutation； or (d) a nilotinib resistant mutation； or (e) a dasatinib resistant mutation； or (f) a T670l mutation in KIT； or (g) a T674l mutation in PDGFR； or (h) T790M mutation in EGFR； or (i) a T315l mutation in abl； or C. a cancer which expresses a mutated molecular target which is a mutated form of BCRabl, c-kit, PDGF, EGF receptor or ErbB2； which method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (l or l&prime；): or a salt, solvate, tautomer or N-oxide thereof.
